Previous 10 | Next 10 |
Gainers: JX Luxventure (LLL) +214%. Draganfly (DPRO) +83%. Zhangmen Education (ZME) +64%. Antelope Enterprise Holdings Limited (AEHL) +37%. Society Pass (SOPA) +31%. Ever-Glory International Group (EVK) +33%. iQIYI (IQ) +26%. Alzamend Neuro (ALZN) +23%. FreightCar America (RAIL) +24%. Puxin (...
Gainers: TCR2 Therapeutics (TCRR) +16%. Precision BioSciences (DTIL) +16%. Alzamend Neuro (ALZN) +15%. BioSig Technologies (BSGM) +13%. Applied Therapeutics (APLT) +13%. Losers: ORIC Pharmaceuticals (ORIC) -29%. Applied Genetic Technologies (AGTC) -28%. NeuroSense Therapeutics (NRSN...
Draganfly DPRO +82% on order for lifesaving drones from Revived Soldiers Ukraine. Troika Media (TRKA) +43%. Enservco (ENSV) +28%. Alzamend Neuro (ALZN) +23%. Kaixin Auto KXIN +18% on new energy logistics vehicles order from Beijing Bujia. Zhihu (ZH) +13%. FreightCar Americ...
InvestorPlace - Stock Market News, Stock Advice & Trading Tips Grab your cup of coffee, investor! We’re starting off the day with a dive into the biggest pre-market stock movers for Tuesday! Source: ventdusud / Shutterstock.com Penny stocks are a hot topic today with man...
Are These Penny Stocks on Your January 2021 Small-Caps List? With penny stocks continuing to trend in the last few weeks, investors are searching for the best small-caps to buy. And, as we barrel toward the end of the year, more traders than ever are looking for ways to make money wit...
Alzamend reported positive results from its phase 1 study using AL001 for the treatment of patients with Alzheimer's Disease. The phase 2 multiple ascending dose study using AL001 treating this patient population is expected to begin Q2 of 2022. AL002 is another shot on goal targe...
What To Know In The Stock Market Today It’s been a long week this week, thanks to wild volatility in the stock market. Today is no different as broader markets pullback. Inflation, virus fears, and interest rate concerns have shaken investors globally. Fears Persist Thanks To...
Disclosing topline data from a Phase 1 trial for AL001, the company’s experimental therapy for Alzheimer’s disease, Alzamend Neuro (ALZN +11.5%) said that the oral lithium-delivery system was equivalent to the currently marketed lithium carbonate products. In its first-in-human ...
Data shows that AL001 is bioequivalent to the marketed lithium carbonate product and the shapes of the lithium plasma concentration versus time curves are similar Alzamend Neuro, Inc. (Nasdaq: ALZN) (“ Alzamend ”), an early clinical-stage biopharmac...
Shares of Alzamend Neuro (ALZN -14.0%), which were up 35% in the prior five trading sessions, are taking a breather today. Shares rose 28% alone yesterday after its ticker was one of the most mentioned on Twitter. The company's lead asset, AL001, is in IND-enabling stage f...
News, Short Squeeze, Breakout and More Instantly...
AstraZeneca PLC (AZN) is expected to report $0.97 for Q2 2024 BJ's Restaurants Inc. (BJRI) is expected to report $0.49 for Q2 2024 Baker Hughes Company (BKR) is expected to report $0.49 for Q2 2024 BlueHarbor Bank (BLHK) is expected to report for Q2 2024 Betterware de Mexico S.A.P...
Alzamend Neuro, Inc. (Nasdaq: ALZN) (“ Alzamend ”), a clinical-stage biopharmaceutical company focused on developing novel products for the treatment of Alzheimer’s disease (“ Alzheimer’s ”), bipolar disorder (“ BD ”), major de...
Investor had agreed to purchase up to $25 million of preferred shares Alzamend expects to use proceeds to further its clinical trials and working capital purposes Alzamend Neuro, Inc. (Nasdaq: ALZN) (“ Alzamend ”), a clinical-stage biopharmaceutical compa...